Plant Cell Culture Perfusion Patents: Leaders & Filing Trends 2026
- Filings jumped 450% from 2021 to 2024, the fastest complete-year stretch in the dataset, before the usual 18-month publication lag understates 2025-2026.
- The top 5 assignees hold 30.5% of all 285 records, while the top 10 combined reach 47.0% — concentrated at the head with a long tail of single- or few-filing entrants below tenth place.
- C12M bioreactor apparatus claims sit in just 29.8% of records, far behind C12N genetic-engineering claims at 81.4%, pointing to equipment and process control as the thinner-claimed side of this field.
Filing growth compares 2021 (2 records) with 2024 (11) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 285 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks 285 published records filed against plant cell, tissue and suspension culture methods where the claims touch perfusion-style operating parameters — perfusion rate, bleed control, residence time, nutrient renewal, waste removal or steady-state operation — and sit within C12N5/04, A01H4/00 or C12M3/00. The scope spans transgenic protein production, plant tissue propagation and bioreactor apparatus claims that reference these operating parameters, rather than plant breeding or culture media composition alone.
Records run from 2015 through the 2026-07-31 data cut-off. Because publication typically lags filing by around 18 months, the most recent one to two years in any trend chart are still filling in and should be read as a floor, not a ceiling.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 285-record set: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
A steep, recent climb
Filings rose from 2 in 2021 to 11 in 2024, a 450% increase over that three-year span, with a peak of 19 records in 2023. Treat 2025 and 2026 figures as undercounts until later publications catch up.
Where the claims concentrate
C12N (microorganisms and genetic engineering) appears in 81.4% of records and A01H (plant breeding) in 60.4%, making genetic and breeding claims the dominant layer. C12M (bioreactor apparatus) trails at 29.8%, and downstream categories like C07K peptides (21.8%) and A61K medicinal preparations (14.4%) show the field's pull toward biologics production rather than pure agronomy.
Shares are the percentage of the 285 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Plant Cell Culture Perfusion Culture with Eureka
This page is one run against one query. Ask Eureka your own question about plant cell culture perfusion culture and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
US20100112700A1 — Large scale disposable bioreactor
A reusable, disposable device for culturing plant tissues or cells including a non-rigid container having dimensions and gas exchange ports designed for maintaining oxygen saturation and shear forces suitable for culturing plant tissue or cells in 400 liters or more of culture medium is provided. Also provided are methods for producing a catalytically active human recombinant protein in a plant cell, using the disposable device of one of the embodiments of the instant specification.Filed by Protalix Ltd., published 2010-05-06.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US7884262B2 | Modified DMO enzyme and methods of its use | 1,158 |
| 2 | US20040019927A1 | Polynucleotides and polypeptides in plants | 305 |
| 3 | WO1993023555A1 | Cultured taxus tissues as a source of taxol, related taxanes and other novel Anti-tumor/Anti-viral compounds | 247 |
| 4 | US6441277B1 | Expression of fructose 1,6 bisphosphate aldolase in transgenic plants | 225 |
| 5 | US6663906B2 | Expression of fructose 1,6 bisphosphate aldolase in transgenic plants | 208 |
| 6 | US5618988A | Enhanced carotenoid accumulation in storage organs of genetically engineered plants | 184 |
| 7 | US5525716A | LPT2 promoter having aleurone-tissue-specific activity | 146 |
| 8 | US4668632A | Sparger and apparatus for and method of growing cells | 105 |
| 9 | US20080317731A1 | Phospholipases, Nucleic Acids Encoding Them and Methods for Making and Using Them | 95 |
| 10 | US20060162006A9 | Polynucleotides and polypeptides in plants | 94 |
Citation counts favour older filings inside any searched corpus — read them as a measure of influence on later work, not as a signal of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four patterns stand out once the records are grouped by year, class and assignee.
A concentrated head, a long tail below it
The top 5 assignees combined hold 30.5% of all 285 records and the top 10 reach 47.0%, meaning over half the field is spread across the remaining ranked entrants and unranked filers. A new entrant is not competing against one dominant player but against a cluster of five to ten active filers plus dozens of occasional ones.
Filing activity accelerated sharply, then the count file is still filling
Filings moved from 2 in 2021 to 11 in 2024, a 450% rise across the last three complete years, with the single busiest year so far being 2023 at 19 records. Because of the roughly 18-month publication lag, 2025 and 2026 numbers will keep rising as later filings surface.
Genetic claims dominate; apparatus claims lag
C12N (microorganisms and genetic engineering) touches 81.4% of the 285 records while C12M (bioreactor apparatus) touches only 29.8%. That gap suggests the equipment and process-control side of perfusion culture — the actual hardware for bleed control and nutrient renewal — carries less claim density than the biology it feeds.
US filings lead, but PCT and EPO both carry weight
The United States receives 113 filings, ahead of the EPO at 35 and WIPO/PCT at 28, with Australia, Canada and Japan following. A filer weighing where to seek protection first should note that PCT filings (28) already outnumber several individual national offices, signalling that a meaningful share of applicants are keeping jurisdictional options open rather than committing early.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to plant cell culture perfusion culture, with the prior art for and against each one.
The assignee landscape
100 companies make up the full ranked list the data endpoint returns for this scope — not a curated top 50 or top 100, but the entire ranking. The leader holds 24 records; fifth place holds 13; tenth place holds 8, showing a fairly gentle drop-off rather than a single runaway leader.
One clear leader, not a runaway monopoly
The top-ranked assignee holds 24 of the 285 records in scope. That is a meaningful lead but not an overwhelming one — fifth place still holds 13 records, so the gap between first and fifth is proportional rather than a cliff.
The top 10 is a real cluster, not a formality
Tenth place holds 8 records, and the top 10 combined account for 47.0% of all 285 records. Any new filer entering this space is realistically competing against a group of ten active players, not a single incumbent.
Co-filing is limited and concentrated
Only 10 co-assignee pairs appear across the dataset, and the strongest recurring pairings involve the same lead assignee working repeatedly with a small set of named inventors. Cross-company joint filing is rare here; most activity is filed by a single assignee acting alone.
| Assignee | Recent year | YoY |
|---|---|---|
| Agrigenetics Inc. | 0 | — |
| Pluri Biotech Ltd. | 0 | -100% |
| ArborGen Inc. | 0 | — |
| Protalix Ltd. | 0 | — |
| Monsanto Technology LLC | 0 | — |
| Fraunhofer Gesellschaft zur Forderung der angewandten Forschung e.V. | 0 | — |
| Verenium Corp | 0 | — |
| Syngenta Crop Protection AG | 0 | — |
Where to take this
The dataset points to specific next steps depending on whether you are scoping freedom-to-operate or looking for a filing angle.
Check the apparatus gap before drafting claims
With C12M bioreactor apparatus claims present in only 29.8% of records against 81.4% for genetic engineering, hardware-level claims around perfusion control equipment may face a thinner prior-art field than biology-side claims.
Explore apparatus claims in EurekaMap the top 10 assignees' current portfolios
Because the top 10 hold 47.0% of all records, a freedom-to-operate review should start with their most recent filings rather than the full 100-entry ranking.
Run an assignee deep-dive in EurekaWatch the 2023-2024 filing spike for signal
The 450% rise from 2021 to 2024 and the 2023 peak of 19 records suggest renewed commercial interest; tracking who filed in that window flags likely near-term competitors.
Track recent filings in EurekaCommon questions about this landscape
This landscape identifies 285 published records that combine plant cell, tissue or suspension culture with perfusion-related operating parameters such as perfusion rate, bleed control, residence time or steady-state operation, filtered to IPC classes C12N5/04, A01H4/00 and C12M3/00. This is a scoped figure based on a specific search string, not a count of every patent that mentions plant cell culture. Broader or narrower keyword and classification choices would produce a different total, so treat 285 as the size of this defined dataset rather than the size of the field as a whole.
The ranked list covers 100 assignees, with the leader holding 24 of the 285 records, fifth place holding 13, and tenth place holding 8. The top 5 assignees together account for 30.5% of all records and the top 10 account for 47.0%, meaning the field has a genuine leading cluster but is far from a single-company monopoly. Most of the remaining ranked entrants and unranked filers hold only one or a handful of records each, forming a long tail typical of an active but not yet consolidated technology area.
Yes, based on complete-year data: filings rose from 2 in 2021 to 11 in 2024, a 450% increase, with the busiest single year so far being 2023 at 19 records. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures in the raw trend are understated and will rise as later filings are published. Read the growth as continuing through the most recent complete year rather than assuming any apparent tapering in the newest years reflects a real slowdown.
US20100112700A1, filed by Protalix Ltd. and published in 2010, claims a reusable, disposable, non-rigid container for culturing plant tissue or cells at 400 liters or more, with gas exchange ports designed to maintain oxygen saturation and appropriate shear forces, alongside a method for producing a catalytically active human recombinant protein in plant cells using that device. It is a representative record for large-scale disposable plant cell bioreactor design, not necessarily the sole barrier in this space. Anyone designing a similar large-volume disposable culture vessel with comparable gas-exchange or shear-control features should review its specific claim language directly rather than assume it is the only relevant prior art, since 285 records populate this landscape overall.
Relative to the 81.4% of records touching C12N genetic engineering claims, C12M bioreactor apparatus claims appear in only 29.8% of records, suggesting hardware and process-control aspects of perfusion culture — such as bleed-control valve design, in-line residence-time sensing, and steady-state nutrient renewal control loops — carry lower claim density than the underlying biology. This does not mean these areas are unpatented, but it indicates comparatively more open claim space than the genetic engineering and plant breeding categories that dominate the dataset. Anyone considering a hardware-focused filing should verify the specific sub-area against current records before assuming it is open.
Research Plant Cell Culture Perfusion Culture in depth with Eureka
Go past this page: query the whole plant cell culture perfusion culture corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.